A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control (ABC) in Patients With Pancreatic Cancer
In this study, 10 patients undergoing treatment for pancreatic cancer using ABC will undergo
three CT scans in addition to their treatment planning simulation CT, during the first,
third and fifth week of a five week course of chemoradiation. These will assess motion of
their pancreatic tumors by tracking the implanted gold fiducial markers to assess intra and
inter-fraction reproducibility. The patients would hold their breath 3 times during which a
CT of the abdomen would be performed.. The intent of this study is to utilize these markers
to gain understanding of pancreas motion for patients treated using ABC to limit this
motion, and the reproducibility of ABC use during and between treatments. The results of
this study would allow us to further refine the radiation delivery margins for future
patients undergoing this treatment. This study would be purely observational and we do not
anticipate the use of this information to affect the current patients on study.
Observational
Observational Model: Case-Only, Time Perspective: Prospective
Characterize patient-specific intra- and inter-fraction target movement (measure in millimeters) in pancreatic cancer patients undergoing radiation treatment with active breathing control.
5 weeks
No
Mary Feng, MD
Principal Investigator
University of Michigan
United States: Food and Drug Administration
HUM00050677
NCT01832142
January 2012
January 2015
Name | Location |
---|---|
University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan 48109-0752 |